Introduction / Welcome

Ubavka DeNoble, MD
Corporate Vice President, Phase II/III, Key Accounts

Nicholas Traynor,
Manager Business Development Clinical Research Services

• Value-based assessment of new medicines is driving convergence of Regulatory, Clinical and Commercial perspectives earlier in the R&D process
• Examples of a more collaborative framework, by which sponsors, regulators, and payers, as essential stakeholders, undertake drug development with reimbursement in mind to achieve the common goal of safe, effective, and affordable medicines
• Paving the way for success' – How commercialization models support more efficient, integrated development

• Overview of industry technology trends
• Making technology simpler and more efficient for our users, in particular site personnel – examples and site feedback
• Consolidating and presenting operational data from multiple systems for effective and timely decision making
• Building from this to realise targeted monitoring efficiencies

In todays' world, observational data are required to make your new product a success - especially after launch. Early planning will ensure you have the appropriate data available by the time your new product goes to market; you will also have time to design the studies in the most cost efficient manner, whilst optimizing data quality and physician interest.

Podiums discussion:
"What I want to change tomorrow" – "take aways" from the seminar and how do we apply this information to the real world.

Chair:
Christian Buhlmann,
Vice President Business Development Clinical Research Services

Elaine Tatum, PhD
Senior Director Business Development Clinical Research Services

Special guest from the Pharmaceutical Industry